Related Experiment Video
Updated: Jun 8, 2025
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
Published on: August 18, 2023
Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced
Megan Cole1, Panayiotis Anastasiou1, Claudia Lee2
1Oncogene Biology Laboratory, Francis Crick Institute, London, UK.
Abstract:
Kirsten rat sarcoma virus (KRAS)-G12C inhibition causes remodeling of the lung tumor immune microenvironment and synergistic responses to anti-PD-1 treatment, but only in T cell infiltrated tumors. To investigate mechanisms that restrain combination immunotherapy sensitivity in immune-excluded tumors, we used imaging mass cytometry to explore cellular distribution in an immune-evasive KRAS mutant lung cancer model. Cellular spatial pattern characterization revealed a community where CD4+ and CD8+ T cells and dendritic cells were gathered, suggesting localized T cell activation. KRAS-G12C inhibition led to increased PD-1 expression, proliferation, and cytotoxicity of CD8+ T cells, and CXCL9 expression by dendritic cells, indicating an effector response. However, suppressive regulatory T cells (Tregs) were also found in frequent contact with effector T cells within this community. Lung adenocarcinoma clinical samples showed similar communities. Depleting Tregs led to enhanced tumor control in combination with anti-PD-1 and KRAS-G12C inhibitor. Combining Treg depletion with KRAS inhibition shows therapeutic potential for increasing antitumoral immune responses.
Insights
KRAS-G12C inhibition combined with anti-PD-1 therapy shows promise for lung cancer. Depleting regulatory T cells (Tregs) enhances anti-tumor immune responses, suggesting a new therapeutic strategy.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- KRAS-G12C inhibition can remodel the tumor immune microenvironment and synergize with anti-PD-1 therapy, but efficacy is limited in immune-excluded tumors.
- Understanding mechanisms that limit combination immunotherapy sensitivity in immune-excluded lung cancer is crucial.
Purpose of the Study:
- To investigate the mechanisms restraining combination immunotherapy sensitivity in immune-evasive KRAS-mutant lung cancer.
- To explore cellular distribution and interactions within the tumor immune microenvironment using imaging mass cytometry.
Main Methods:
- Utilized imaging mass cytometry to analyze cellular spatial patterns in an immune-evasive KRAS-mutant lung cancer model.
- Characterized immune cell communities, including T cells and dendritic cells, and their spatial relationships.
- Investigated the impact of KRAS-G12C inhibition on T cell responses and the role of regulatory T cells (Tregs).
Main Results:
- KRAS-G12C inhibition increased PD-1 expression, proliferation, and cytotoxicity of CD8+ T cells, alongside CXCL9 expression by dendritic cells.
- Identified suppressive regulatory T cells (Tregs) in close proximity to effector T cells within immune communities.
- Depletion of Tregs enhanced tumor control when combined with anti-PD-1 therapy and a KRAS-G12C inhibitor in preclinical models.
- Similar immune cell communities were observed in human lung adenocarcinoma samples.
Conclusions:
- KRAS-G12C inhibition can induce effector immune responses but is counteracted by suppressive Tregs in immune-excluded tumors.
- Depleting Tregs in combination with KRAS inhibition and anti-PD-1 therapy demonstrates significant therapeutic potential for enhancing antitumoral immunity.
- This combination strategy may overcome resistance to immunotherapy in KRAS-mutant lung cancers.
